Showing results (51-60 of 82) with videos related to
Sort By:
Pageof 9
Proceedings of the National Academy of Sciences of the United States of America|December 20, 2011
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epitheliumJustin M Balko, Todd W Miller, Meghan M Morrison, et al.The Journal of Clinical Investigation|July 23, 2013
MerTK inhibition in tumor leukocytes decreases tumor growth and metastasisRebecca S Cook, Kristen M Jacobsen, Anne M Wofford, et al.Proceedings of the National Academy of Sciences of the United States of America|March 10, 2011
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinaseJoan T Garrett, María Graciela Olivares, Cammie Rinehart, et al.Journal of Cell Science|October 24, 2020
A requirement for p120-catenin in the metastasis of invasive ductal breast cancerSarah J Kurley, Verena Tischler, Brian Bierie, et al.Cell Cycle (Georgetown, Tex.)|January 16, 2015
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cellsKaleigh Canfield, Jiaqi Li, Owen M Wilkins, et al.Cancer Research|May 2, 2013
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signalingChristian D Young, Adam D Pfefferle, Philip Owens, et al.Proceedings of the National Academy of Sciences of the United States of America|August 14, 2013
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesAriella B Hanker, Adam D Pfefferle, Justin M Balko, et al.Cell Death & Disease|January 19, 2018
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancersMichelle M Williams, Linus Lee, Thomas Werfel, et al.Cancer Research|November 11, 2018
Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1Thomas A Werfel, David L Elion, Bushra Rahman, et al.Targeted Oncology|December 9, 2017
Motivation for Launching a Cancer Metastasis Inhibition (CMI) ProgramJill M Pulley, Rebecca N Jerome, Martin L Ogletree, et al.Pageof 9